(NASDAQ: NRXP) Nrx Pharmaceuticals's forecast annual revenue growth rate of 1,549.32% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 114.46%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.4%.
Nrx Pharmaceuticals's revenue in 2026 is $242,000.On average, 6 Wall Street analysts forecast NRXP's revenue for 2026 to be $3,205,658,264, with the lowest NRXP revenue forecast at $1,101,426,978, and the highest NRXP revenue forecast at $7,121,905,516. On average, 4 Wall Street analysts forecast NRXP's revenue for 2027 to be $15,135,629,712, with the lowest NRXP revenue forecast at $13,814,760,267, and the highest NRXP revenue forecast at $16,360,405,273.
In 2028, NRXP is forecast to generate $31,244,561,224 in revenue, with the lowest revenue forecast at $28,519,091,405 and the highest revenue forecast at $33,745,250,027.